HGEN - Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Humanigen (HGEN) partners with EVERSANA to make Lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from USFDA and subsequent BLA. Humanigen’s investigational treatment, Lenzilumab, a proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, is designed to prevent and treat cytokine storm, a complication considered to be a leading cause of COVID-19 death.Data showed that up to 89% of hospitalized patients with COVID-19 are hypoxic and at risk of this immune hyper-response, which can trigger acute respiratory distress syndrome in severe cases of COVID-19. HGEN is +3.8% to $17.88Source: Press Release

For further details see:

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment